Krsnaa Diagnostics Share Price

Systematix

• Business Line
• 4 days 20 hours ago

Healthcare Services company Krsnaa Diagnostics announced Q4FY26 & FY26 results Standalone Financial Highlights: Total Income for Q4FY26 stood at Rs 2,044.24 million, a growth of 14.13% YoY compared to Rs 1,791.09 million in Q4FY25 and an increase of 25.24% QoQ from Rs 1,632.27 million in Q3FY26. Revenue from operations for Q4FY26 was Rs 1,730.18 million, showing a marginal decline of 0.94% YoY from Rs 1,746.53 million, but an increase of 8.52% QoQ from Rs 1,594.32 million. Net Profit for Q4FY26 reached Rs 433.82 million, representing a substantial growth of 105.94% YoY from Rs 210.65 million and an increase of 163.05% QoQ from Rs 164.92 million. For FY26, standalone Total Income was Rs 7,343.59 million, up 3.82% YoY compared to Rs 7,073.64 million in FY25. Annual Revenue from operations for FY26 stood at Rs 6,909.47 million, a slight increase of 1.36% YoY from Rs 6,816.95 million. Annual standalone Net Profit for FY26 was Rs 1,026.75 million, witnessing a growth of 23.99% YoY from Rs 828.08 million in the previous year. Earnings Per Share (Basic) for FY26 increased to Rs 31.69 from Rs 25.65 in FY25. Consolidated Financial Highlights: Total Income for Q4FY26 was Rs 2,241.03 million, an increase of 17.66% YoY from Rs 1,904.64 million and up 21.16% QoQ from Rs 1,849.69 million in Q3FY26. Revenue from operations for Q4FY26 stood at Rs 1,926.04 million, up 3.51% YoY from Rs 1,860.76 million and up 6.29% QoQ from Rs 1,812.01 million. Net Profit (attributable to owners) for Q4FY26 reached Rs 417.18 million, reflecting a robust growth of 101.75% YoY from Rs 206.78 million and an increase of 173.63% QoQ from Rs 152.46 million. For FY26, consolidated Total Income reached Rs 8,161.64 million, a growth of 9.89% YoY from Rs 7,426.95 million in FY25. Annual consolidated Revenue from operations for FY26 was Rs 7,727.74 million, up 7.75% YoY from Rs 7,171.60 million. Annual consolidated Net Profit for FY26 stood at Rs 1,014.31 million, showing a YoY increase of 30.70% from Rs 776.08 million in FY25. Consolidated Earnings Per Share (Basic) for FY26 was Rs 31.30, compared to Rs 24.04 in the previous year. Business Highlights: Segment Performance: The Group's operations predominantly relate to providing diagnostic services in radiology and pathology. It operates as a single reportable segment. Final Dividend: The Board of Directors has recommended a final dividend of Rs 2/- per equity share of face value Rs 5/- each (representing 40% of the face value) for FY25-26. Associate Derecognition: During the year, the Company ceased to have significant influence over Apulki Healthcare Private Limited. The retained investment was fair valued, resulting in a gain of Rs 258.75 million (net of deferred tax - Rs 221.75 million), which was recognized under Other Income. Auditor Appointments: The Board approved the recommendation to appoint M/s Kirtane & Pandit LLP as Statutory Auditors for a five-year term starting from FY26-27. M/s Mahajan & Aibara were re-appointed as Internal Auditors and Harshad S. Deshpande & Associates as Cost Auditors for FY26-27. Tax Demand and Appeals: The Company received demand orders totaling Rs 626.90 million from Income Tax authorities for multiple assessment years. The Company has filed appeals against these orders and has deposited Rs 102.77 million under protest on a consolidated basis. Labour Code Provisions: The Company reassessed incremental liabilities arising from the New Labour Codes, resulting in a net impact of Rs 93.18 lakhs recognized in the Statement of Profit and Loss for FY26. Yash Mutha, Managing Director, said: "FY26 marks a year of deliberate and disciplined investment into the long-term architecture of Krsnaa Diagnostics, and the results reflect both the strength of our operating model and the early dividends of our strategic initiatives. On a consolidated basis, we achieved revenue of Rs 7,728 million with reported Profit After Tax growing a robust 31% to Rs 1,014 million, the highest reported PAT in the Company's history since listing. The reported PAT includes fair valuation gain of the investment in Apulki Healthcare Private Limited, amounting to Rs 221.75 million. The Diluted EPS of Rs 30.88 is a 31% improvement over the prior year. Our operating cash flows strengthened significantly to Rs 1,431 million in FY26 compared to Rs 873 million in FY2025, an improvement of approximately 64% year-on-year, demonstrating the structural improvement in our collections framework and working capital management. The Board has recommended a final dividend of Rs 2/- per share of face value Rs 5/-, and with a well-defined and well-funded growth roadmap anchored in long-term PPP contracts, a rapidly scaling B2C vertical, and a transformative entry into tertiary care through Apulki Healthcare, we remain deeply committed to building a platform that delivers enduring and compounding value to all our stakeholders." Mitesh Dave, Group CEO, said: "FY26 represents a pivotal inflection point in Krsnaa Diagnostics' growth journey, marked not only by strong headline financial performance but more significantly by the accelerated emergence of our retail diagnostics vertical, Krsnaa Retail Private Limited, as a structurally important and independently scalable growth engine for the Group. Within just twelve months of focused scaling, our retail vertical delivered a 8 times jump in revenue and a 7 times surge in touchpoints, expanding to 3,500 locations across 5 states, a pace of growth that firmly establishes Krsnaa Retail as one of the country's most formidable retail diagnostics growth stories. As we enter FY27, we remain focused on disciplined execution, transparency, and strong governance standards, while continuing to uphold the trust placed in us by our investors, partners, and patients." Result PDF

• Trendlyne
• 6 days 1 hour ago

Conference Call with Krsnaa Diagnostics Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 3 months 3 weeks ago